Pharming Group N.V. EBIT

The latest EBIT for PHAR is $6.2B as of June 2026. That compares with $18M in the prior-year period — up 34795.9% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Pharming Group N.V.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, PHAR's EBIT moved from $18M to $6.2B — a 34795.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pharming Group N.V.'s operating scale or balance-sheet position.

Against Healthcare companies, PHAR currently prints $6.2B for EBIT, while the sector average sits near $22B. That is roughly 72.2% below the sector mean. Large gaps often invite a closer look at Pharming Group N.V.'s growth, margins, and balance sheet.

A EBIT figure of $6.2B for PHAR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting PHAR's EBIT ($6.2B), review year-over-year change from $18M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.